Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Cited by (374)

Items 201–300 of 374

1. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures
   Yuen‐Yi Tseng, Jesse S. Boehm · 2019 · Current Opinion in Genetics & Development
2. A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer
   Stefano Guadagni, Marco Clementi, Francesco Masedu, Giammaria Fiorentini, Donatella Sarti, Marcello Deraco M. D, Shigeki Kusamura M. D, Ioannis Papasotiriou, Panagiotis Apostolou, Karl Reinhard Aigner et al. · 2020 · International Journal of Molecular Sciences
3. B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia
   Sigrid Strand Skånland, Linda Karlsen, Kjetil Taskén · 2020 · Scandinavian Journal of Immunology
4. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
   Peter Valent, Alberto Órfão, Stefan Kubicek, Philipp Bernhard Staber, Torsten Haferlach, Michael W. Deininger, Karoline Kollmann, Thomas Lion, Irene Johanna Virgolini, Georg E. Winter et al. · 2021 · HemaSphere
5. Drug sensitivity testing, a unique drug selection strategy
   Da-Yong Lu, Ting-Ren Lu · 2020 · Advances in Biomarker Sciences and Technology
6. Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells
   Alexandra L. Pourzia, Michael Olson, Stefanie R. Bailey, Angela C. Boroughs, Aditi Aryal, Jeremy A. Ryan, Marcela Valderrama Maus, Anthony G. Letai · 2023 · Cell Death and Disease
7. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re‐induction chemotherapy
   Jacqueline Suen Garcia, Shruti Bhatt, Geoffrey G. Fell, Adam Samuel Sperling, Michael W. Burgess, Hasmik Keshishian, Binyam Yilma, Andrew Mark Brunner, Donna S Neuberg, Steven A. Carr et al. · 2019 · American Journal of Hematology
8. Crosstalk between autophagy and apoptosis: Mechanisms and therapeutic implications
   Andrew M. Thorburn · 2020 · Progress in molecular biology and translational science
9. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas
   Denise Müller, Paolo Mazzeo, Raphael Koch, Mark-Sebastian Bösherz, Stefan Welter, Alexander Freiherr von Hammerstein-Equord, Marc Hinterthaner, Lucia Cordes, Djeda Belharazem, Alexander Marx et al. · 2021 · BMC Medicine
10. Computational models for predicting anticancer drug efficacy: A multi linear regression analysis based on molecular, cellular and clinical data of oral squamous cell carcinoma cohort
    Beaulah Mary Robert, Brindha G R, B. Santhi, Govindasamy Kanimozhi, Nagarajan Rajendra Prasad · 2019 · Computer Methods and Programs in Biomedicine
11. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
    Louise Walsh, Kathryn E. Haley, Bruce Moran, Brian Mooney, Finbarr Tarrant, Stephen F. Madden, Alessandra Di Grande, Yue Fan, Sudipto Das, Oscar M. Rueda et al. · 2019 · Clinical Cancer Research
12. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
    Antonella Montinaro, Itziar Areso Zubiaur, Julia Saggau, Anna-Laura Kretz, Rute M. M. Ferreira, Omar Hassan, Ella F Kitzig, Ines Müller, Mona A El-Bahrawy, Silvia von Karstedt et al. · 2021 · Cell Death and Differentiation
13. Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
    Júlia López, Àngela Llop‐Hernández, Sara Verdura, Eila Serrano‐Hervás, Eva Martinez‐Balibrea, Joaquim Bosch‐Barrera, Eduard Teixidor, Eugeni López‐Bonet, Begoña Martı́n-Castillo, Josep Sardanyés A et al. · 2025 · Cell Death Discovery
14. RNA Pol II inhibition activates cell death independently from the loss of transcription
    Nicholas W. Harper, Gavin A Birdsall, Megan E. Honeywell, Kelly M. Ward, Athma A. Pai, Michael J. Lee · 2025 · Cell
15. KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer
    Ye Yang, Zhenyu Sang, Jie Ma, Yaping Zhu, Sufang Wu · 2021 · Translational Cancer Research
16. The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine
    Isacco Ferrarini, Antonella Rigo, Carlo Visco · 2022 · Haematologica
17. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
    Martin A. Grundy, Claire Seedhouse, Thomas Jones, Liban Elmi, Michael Hall, Adam Graham, Nigel H. Russell, Monica Pallis · 2018 · PLoS ONE
18. Precise prediction of multiple anticancer drug efficacy using multi target regression and support vector regression analysis
    Brindha G R, B.S. Rishiikeshwer, B. Santhi, K. Nakendraprasath, R. Manikandan, Amir H. Gandomi · 2022 · Computer Methods and Programs in Biomedicine
19. Nanosonodynamic effect-promoted mitochondrial dysfunction augments calcium overload for Gasdermin E-induced pyroptotic antitumor therapy
    Zheng Zhang, Xin Zhang, Shuangshuang Zhao, Caihong Dong, Wei Feng, Yu Chen, Li Ding, Yu Chen, Baoding Chen · 2022 · Chemical Engineering Journal
20. Phenotypic selection with an intrabody library reveals an anti-apoptotic function of PKM2 requiring Mitofusin-1
    Tong Liu, Tomomi Kuwana, Hongkai Zhang, Matthew G. Vander Heiden, Richard Alan Lerner, Donald D. Newmeyer · 2019 · PLoS Biology
21. Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
    Ximena Rosas-Plaza, Gerda de Vries, Gert Jan Meersma, Albert J.H. Suurmeijer, Jourik A. Gietema, Marcel A.T.M. van Vugt, Steven de Jong · 2019 · Molecular Cancer Therapeutics
22. Counting on Death – Quantitative aspects of Bcl‐2 family regulation
    Annika Hantusch, Markus Rehm, Thomas Brunner · 2018 · FEBS Journal
23. BioID-based proteomic analysis of the Bid interactome identifies novel proteins involved in cell-cycle-dependent apoptotic priming
    Robert Pedley, Louise King, Venkatesh Mallikarjun, Pengbo Wang, Joe Swift, Keith R. Brennan, Andrew P. Gilmore · 2020 · Cell Death and Disease
24. The prospects of tumor chemosensitivity testing at the single-cell level
    Chuan Yang, Caibo Yang, Yosef Yarden, Kenneth K.W. To, Liwu Fu · 2020 · Drug Resistance Updates
25. Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes
    Moom Rahman Roosan, Shelley M. MacNeil, David F. Jenkins, Gajendra Shrestha, Sydney R. Wyatt, Jasmine A. McQuerry, Stephen Piccolo, Laura M. Heiser, Joe W. Gray, William Evan Johnson et al. · 2017 · Genome Medicine
26. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53
    Caroline Capdevielle, Angélique Desplat, Justine Charpentier, Francis A. Sagliocco, Pierre Thiébaud, Nadine Thézé, Sandrine Fédou, Katarzyna B. Hooks, Romano Silvestri, Veronique Guyonnet‐Dupérat et al. · 2019 · Neuro-Oncology
27. TTF1-NPs Induce ERS-Mediated Apoptosis and Inhibit Human Hepatoma Cell Growth In Vitro and In Vivo
    Bin Xiao, Chao Liu, Bing-tong Liu, Xuan Zhang, Rongrong Liu, Xuewu Zhang · 2016 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
28. MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
    Clara Alcon, Fernando Martín, Estela Prada, Jaume Mora, Aroa Soriano, Gabriela Guillén, Soledad Gallego, Josep M Roma, Josep Samitier, Alberto Villanueva et al. · 2022 · Cell Death Discovery
29. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation
    Stefanie Enzenmüller, Alexandra Niedermayer, Felix Seyfried, Vera Muench, Daniel Tews, Ulrich Rupp, Eugen Tausch, Alexander Groß, Pamela Fischer‐Posovszky, Paul Walther et al. · 2024 · Cell Death and Disease
30. Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma
    Elizabeth G. Fernandez, Wilson X. Mai, Kai Song, Nicholas A. Bayley, Jiyoon Kim, Henan Zhu, Marissa S. Pioso, Pauline Young, Cassidy L. Andrasz, Dimitri Cadet et al. · 2024 · Nature Communications
31. Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer
    Travis Vander Steen, Ingrid C. Espinoza, Cristina Duran, Guillem Casadevall, Eila Serrano‐Hervás, Elisabet Cuyàs, Sara Verdura, George W. Kemble, Scott H. Kaufmann, Robert R. McWilliams et al. · 2025 · Neoplasia
32. Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics
    Cristina E. Tognon, Rosalie C. Sears, Gordon Brent Mills, Joe W. Gray, Jeffrey W Tyner · 2020 · Annual Review of Cancer Biology
33. Sab concentrations indicate chemotherapeutic susceptibility in ovarian cancer cell lines
    Iru Paudel, Sean Hernandez, Gilda M. Portalatin, Tara P. Chambers, Jeremy W. Chambers · 2018 · Biochemical Journal
34. Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
    Elyse A. Olesinski, Karanpreet Singh Bhatia, Chuqi Wang, Marissa S. Pioso, Xiao Xian Lin, Ahmed M. Mamdouh, Shu Xuan Ng, Vedant Sandhu, Shaista Shabbir Jasdanwala, Binyam Yilma et al. · 2024 · Blood Cancer Discovery
35. Prospects for Venetoclax in Myelodysplastic Syndromes
    Jacqueline Suen Garcia · 2019 · Hematology/Oncology Clinics of North America
36. Mechanisms of cyclic AMP/protein kinase A- and glucocorticoid-mediated apoptosis using S49 lymphoma cells as a model system
    Malik M. Keshwani, Joan R. Kanter, Yuliang Ma, Andrea Scarpa Wilderman, Manjula Darshi, Paul A. Insel, Susan Serota Taylor · 2015 · Proceedings of the National Academy of Sciences
37. E2F1 interacts with BCL‐xL and regulates its subcellular localization dynamics to trigger cell death
    Céline Vuillier, Steven Lohard, Aurélie Fétiveau, Jennifer Allègre, Cémile Kayaci, Louise E King, Frédérique Braun, Sophie Barillé‐Nion, Fabien Gautier, Laurence Dubrez et al. · 2017 · EMBO Reports
38. Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
    Karanpreet Singh Bhatia, Vedant Sandhu, Mei Hsuan Wong, Prasad Iyer, Shruti Bhatt · 2024 · Frontiers in Oncology
39. Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells
    Bahriye Karakaş, Yeliz Aka, Aslı Giray, Şehime Gülsün Temel, Ufuk Acikbas, Hüveyda Başağa, Özgür Gül, Özgür Kütük · 2021 · Cell Death Discovery
40. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy
    Albert Manzano-Muñoz, José Yeste, María Alejandra Ortega, Fernando Martín, Anna López, Jordi Rosell, Sandra Castro, César Serrano, Josep Samitier, Javier Ramón‐Azcón et al. · 2022 · npj Precision Oncology
41. Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?
    Sophie Barillé‐Nion, Steven Lohard, Philippe Paul Juin · 2020 · Biomolecules
42. Patient-derived model systems and the development of next-generation anticancer therapeutics
    Nikolaus Krall, Giulio Superti‐Furga, Gregory Ian Vladimer · 2020 · Current Opinion in Chemical Biology
43. Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
    Viacheslav V. Senichkin, Nikolay V. Pervushin, Alexey V. Zamaraev, Elena V. Sazonova, Anton P. Zuev, Alena Y. Streletskaia, Tatiana A. Prikazchikova, Timofei S. Zatsepin, Olga Vladimirovna Kovaleva, Elena M. Tchevkina et al. · 2021 · Cancers
44. LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
    Li, Chendi, Syed, Mohammed Usman, Nimbalkar, Anahita, Shen, Yi, Vieira, Melissa D., Fraser, Cameron, Inde, Zintis, Qin, Xingping, Ouyang, Jian, Kreuzer, Johannes et al. · 2025 · Nature Communications
45. Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition
    Sana Chaudhry, Felipe Beckedorff, Shaista Shabbir Jasdanwala, Tulasigeri M. Totiger, Maurizio Affer, Abimbola Eunice Lawal, Skye Montoya, Francesco Tamiro, Olivia Tonini, Alexandra Chirino et al. · 2024 · Leukemia
46. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer
    Shawn J. Rice, Xin Liu, Hong‐Gang Wang, Chandra Prakash Belani · 2019 · PLoS ONE
47. Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
    Martin A. Grundy, Thomas Jones, Liban Elmi, Michael Hall, Adam Graham, Nigel H. Russell, Monica Pallis · 2018 · PLoS ONE
48. Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X L degradation to overcome cancer chemoresistance
    Xingping Qin, Adam G. Presser, Lissah Johnson, Yusuke Matoba, Brendan Shay, Weiyi Xu, Jonathan Choiniere, Cameron Fraser, Filip Garbicz, Johan K. E. Spetz et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
49. Anticancer Drug Development: Evaluative Architecture
    Da-Yong Lu, Bin Xu, Ting-Ren Lu · 2022 · Letters in Drug Design & Discovery
50. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis
    Remya Nair, An H. Vu, Abigail Kathryn Freer, Karanpreet Singh Bhatia, Dongxue Wang, Milan R. Savani, Shannon M. Matulis, Sagar Lonial, David L. Jaye, Lawrence Boise et al. · 2024 · Blood
51. Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting
    Zhe Wang, Mutian Tang, Marina Konopleva · 2026 · Oncogenesis
52. Deep sequencing and automated histochemistry of human tissue slice cultures improve their usability as preclinical model for cancer research
    Susann Haehnel, Kristin Reiche, Dennis Löffler, Andreas Horn, Conny Blumert, Sven-Holger Puppel, Nicole C. Kaiser, Felicitas Rapp, Michael Rade, Friedemann Horn et al. · 2019 · Scientific Reports
53. MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia
    Albert Manzano-Muñoz, Clara Alcon, Pablo R. Menéndez, Manuel R. Ramírez, Felix Seyfried, Klaus‐Michael Debatin, Lüder Hinrich Meyer, Josep Samitier, Joan Montero · 2021 · Frontiers in Cell and Developmental Biology
54. Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity
    Taojun Ye, Anqi Lin, Zhengang Qiu, Shulu Hu, Chaozheng Zhou, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo · 2023 · iScience
55. BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics
    Rongqing Aaron Pan, Youzhen Wang, Shumei Qiu, Mariana Villalobos-Ortiz, Jeremy A. Ryan, Erick Morris, Ensar Halilovic, Anthony G. Letai · 2023 · Haematologica
56. Traditionally Used Medicinal Dendrobium: A Promising Source of Active Anticancer Constituents
    Mukti Ram Paudel, Hari Datta Bhattarai, Bijaya Pant · 2020 · Reference series in phytochemistry
57. Mitochondria dysfunction in circulating tumor cells
    Chiara Agnoletto, Stefano Volinia · 2022 · Frontiers in Oncology
58. Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
    Elyse A. Olesinski, Shruti Bhatt · 2021 · STAR Protocols
59. In Situ Ratiometric Fluorescence Imaging for Tracking Targeted Delivery and Release of Anticancer Drug in Living Tumor Cells
    Keqin Yang, Jingjin Zhao, Liangliang Zhang, Rongjun Liu, Hong Liang, Shulin Zhao · 2019 · ACS Applied Bio Materials
60. Clinical and Prognostic Significance of Cell Sensitivity to Chemotherapy Detected In Vitro on Treatment Response and Survival of Leukemia Patients
    Maria A. Kolesnikova, Сенькова Александра Васильевна, Sofia Tairova, Овчинников Виктор Сергеевич, Tatiana Ivanovna Pospelova, Зенкова Марина Аркадьевна · 2019 · Journal of Personalized Medicine
61. Translating Public Health Research Into Public Health Practice: Outcomes and Characteristics of Successful Collaborations
    Stuart A. Capper, W. Jack Duncan, Peter M. Ginter, Clyde Barganier, Nancy Blough, Pat Cleaveland · 1996 · American Journal of Preventive Medicine
62. Role of Bcl‐2 inhibition in myelodysplastic syndromes
    Sabine Blum, Γεράσιμος Τσιλιμιδός, Helena Bresser, Michael Lübbert · 2022 · International Journal of Cancer
63. Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response
    Yoshiyuki Tsukamoto, Yuka Hirashita, Tomotaka Shibata, Shoichi Fumoto, Shusaku Kurogi, Chisato Nakada, Keisuke Kinoshita, Takafumi Fuchino, Kazunari Murakami, Masafumi Inomata et al. · 2023 · Cancers
64. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)
    Pablo Velasco, Francisco José Bautista, Alba Rubio‐San‐Simón, Yurena Aguilar de la Red, Susana Rives, José Luís Dapena, Antonio Pérez‐Martínez, Manuel R. Ramírez, Cristina Sáiz-Ladera, Elisa Izquierdo et al. · 2023 · Frontiers in Pediatrics
65. High-Throughput Testing of Novel–Novel Combination Therapies for Cancer: An Idea Whose Time Has Come
    Uciane K. Scarlett, Dennis C. Chang, Thomas J. Murtagh, Keith T. Flaherty · 2016 · Cancer Discovery
66. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
    Matthew L. Hemming, Patrick D. Bhola, Michael A. Loycano, Justin A. Anderson, Madeleine L. Taddei, Leona A. Doyle, Elizaveta Lavrova, Jessica L. Andersen, Kelly S. Klega, Morgan R. Benson et al. · 2022 · Clinical Cancer Research
67. Mitosis and mitochondrial priming for apoptosis
    Robert Pedley, Andrew P. Gilmore · 2016 · Biological Chemistry
68. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy
    R. Taylor Ripley, Deborah R. Surman, Laurence P. Diggs, Jane B. Trepel, Min-Jung Lee, Jeremy A. Ryan, Jeremy L. Davis, Seth M. Steinberg, Jonathan Matthew Hernandez, Choung Hoang et al. · 2018 · BMC Gastroenterology
69. Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients
    Wafik S. El‐Deiry, Catherine Bresson, Fanny Wunder, Benedito A. Carneiro, Don Steven Dizon, Jeremy Lyle Warner, Stephanie L. Graff, Christopher G. Azzoli, Eric T. Wong, Liang Cheng C et al. · 2025 · Oncotarget
70. BCL-xL dependency in chromophobe renal cell carcinoma
    Nadine Mahmoud, Xingping Qin, Wafaa Bzeih, Damir Khabibullin, Michel Alchoueiry, Steven Safi, Joelle Chami, Tiegang Han, Samer Salem, Carmen Priolo et al. · 2025 · Cancer Gene Therapy
71. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan, Danielle M. Brander, Paul M. Barr, Svitlana Tyekucheva, Liam R. Hackett, Mary C. Collins, Stacey M. Fernandes, Yue Ren, Yinglu Zhou, Mikaela M. McDonough et al. · 2023 · Leukemia
72. Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer
    Fernando Martín, Clara Alcon, Elba Marín, Paula Morales-Sánchez, Albert Manzano-Muñoz, Sherley Díaz, M. Lluïsa Pérez García, Josep Samitier, Albert Lu, Alberto Villanueva et al. · 2025 · Cell Death and Disease
73. Studying Cellular Signal Transduction with OMIC Technologies
    Benjamin D. Landry, David C. Clarke, Michael J. Lee · 2015 · Journal of Molecular Biology
74. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer
    Mercè Juliachs, Mireia Pujals, Chiara Bellio, Nathalie Meo-Evoli, Juan M. Durán, Esther Zamora, Mireia Parés, Anna Suñol, Olga Méndez, Álex Sánchez‐Pla et al. · 2022 · Cancers
75. The Role of BCL-2 Proteins in the Development of Castration-resistant Prostate Cancer and Emerging Therapeutic Strategies
    Luke B. Soliman, André Oliveira Souza, Praveen R. Srinivasan, Matthew L. Danish, Paul Bertone, Wafik S. El‐Deiry, Benedito A. Carneiro · 2021 · American Journal of Clinical Oncology
76. Comparing functional and genomic‐based precision medicine in blood cancer patients
    Lukas Kazianka, Alexander Pichler, Christiane Agreiter, Johannes Rohrbeck, Christoph Kornauth, Edit Anna Porpaczy, Christian Sillaber, Wolfgang R. Sperr, Karoline Veronika Gleixner, Alexander W. Hauswirth et al. · 2025 · HemaSphere
77. Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter’s syndrome
    Antonella Rigo, Tiziana Vaisitti, Carlo Laudanna, Eleonora Terrabuio, Matilde Micillo, Cristina Frusteri, Beatrice D’Ulivo, F. Merigo, Andrea Sbarbati, Kevin Mellert et al. · 2024 · Cell Death and Disease
78. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling
    Deborah R. Surman, Yuan Xu, Min-Jung Lee, Jane B. Trepel, Kate Brown, Maheshwari Ramineni, Taylor G. Splawn, Laurence P. Diggs, H. Courtney Hodges, Jeremy L. Davis et al. · 2021 · Molecular Cancer Therapeutics
79. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target
    Yeliz Aka, Bahriye Karakaş, Ufuk Acikbas, Hüveyda Başağa, Özgür Gül, Özgür Kütük · 2021 · The International Journal of Biochemistry & Cell Biology
80. β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
    Remya Nair, Vimal Subramaniam, Benjamin G. Barwick, Vikas Anand Gupta, Shannon M. Matulis, Sagar Lonial, Lawrence Boise, Ajay K. Nooka, Kuzhali Muthumalaiappan, Mala Shanmugam · 2022 · Haematologica
81. A new approach to assess drug sensitivity in cells for novel drug discovery
    Luca Mazzarella, Giuseppe Curigliano · 2018 · Expert Opinion on Drug Discovery
82. Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy
    Javier Abel Menéndez, Ruth Lupu, Begoña Martı́n-Castillo, Josep Sardanyés A, Tomás Alarcón, Sara Verdura, Elisabet Cuyàs · 2025 · Frontiers in Immunology
83. The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL
    Maren Christiane Wichert, Colin Fortner, Alexandra Niedermayer, Johanna Bender, Stefanie Enzenmüller, Klaus‐Michael Debatin, Lüder Hinrich Meyer, Felix Seyfried · 2024 · Blood Advances
84. Establishment and Validation of a Ferroptosis-Related Gene Signature to Predict Overall Survival in Lung Adenocarcinoma
    Su Wang, Zhen Xie, Zeng‐Hong Wu · 2022 · Frontiers in Genetics
85. Integrated Strategies to Gain a Systems-Level View of Dynamic Signaling Networks
    Robert Howard Newman, Jin Zhang · 2017 · Methods in enzymology on CD-ROM/Methods in enzymology
86. Zebrafish Xenographs in Oncology and Personalized Medicine
    Nataliya A. Lunina, Dina R. Safina, Sergey V. Kostrov · 2024 · Molecular Biology
87. Harnessing PUMA's lethal potential: BCL-2 family dynamics and novel strategies to combat cancer recurrence
    Moustafa A. Mansour, Mohamed Abdel-Fattah El-Salamoni, Hamdi Nabawi Mostafa · 2025 · Cancer Treatment and Research Communications
88. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients
    Jeerawan Klangjorhor, Areerak Phanphaisarn, Pimpisa Teeyakasem, Parunya Chaiyawat, Phichayut Phinyo, Jongkolnee Settakorn, Nipon Theera‐Umpon, Dumnoensun Pruksakorn · 2020 · Cancer Chemotherapy and Pharmacology
89. Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
    Da-Yong Lu, Ting-Ren Lu · 2021 · Current Clinical Pharmacology
90. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
    Ramy Rahmé, Thorsten Braun · 2024 · Journal of Clinical Medicine
91. Traditionally Used Medicinal Dendrobium: A Promising Source of Active Anticancer Constituents
    Mukti Ram Paudel, Hari Datta Bhattarai, Bijaya Pant · 2022 · Reference series in phytochemistry
92. Understanding the Functional Dependence and Inhibition of the Bcl-2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine
    Karson J. Kump, Ejaz Ahmad, Charles Elliott Foucar, Rita A. Avelar, Carlos Murga‐Zamalloa, Matthew L. Lieberman, Malathi Kandarpa, Ahmed S.A. Mady, Analisa V. DiFeo, Lin Zhang et al. · 2025 · ACS Pharmacology & Translational Science
93. Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
    Yuan Xu, Cristian G. Medina, Deborah R. Surman, Lacey Elizabeth Dobrolecki, Monica Vilchis, Maheshwari Ramineni, Susan Galloway Hilsenbeck, Yanming Li, Naren Li, Siqi Wu et al. · 2025 · Molecular Cancer Therapeutics
94. Drug Sensitivity Testing for Cancer Therapy, Key Areas
    Da-Yong Lu, Ting-Ren Lu, Nagendra Sastry Yarla, Bin Xu · 2022 · Reviews on Recent Clinical Trials
95. Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia
    Philipp Makowka, Verena Stolp, Karoline Stoschek, Hubert L. Serve · 2021 · Biological Chemistry
96. Distributed learning and prediction modelling in radiation oncology
    Deist · 2019
97. Bone Cancer and Metastasis Trials, Drug Treatment
    Da-Yong Lu, Bin Xu · 2021 · Acta Scientific Orthopaedics
98. Two-photon phototherapy-mediated activation of natural killer cell immunity for targeted elimination of post-treatment residual hepatocellular carcinoma
    Yubo Tan, Yibo An, Yisheng Peng, Man Li, Ziying Wang, Renyuan Liu, Dazhuang Xu, Xinyu Tan, Peiyu Wang, Yaohui He et al. · 2025 · Chemical Engineering Journal
99. Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure
    Tooba Jawwad, Sadaf Khursheed Baba, Anju Surendranath, Elena Chaudhary, Ghulam Jeelani, Ammira S. Al-Shabeeb Akil, Asma Al Menhali, Ajaz A. Bhat, Sameer Mirza · 2026 · Journal of Translational Medicine
100. Development of a Novel Biomarker Platform for Profiling Key Protein–Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs
     Andrew J Kinloch, Faiyaz Rahman, Bahriye Karakaş, Muhammad Shahid, Bora Lim, Stephanie J. Bouley, James A. Walker, Erinna F. Lee, Walter Douglas Fairlie, Kevin R. Kelly et al. · 2025 · Cancers